· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 25, 2005
Subject: Association of Aranesp® (darbepoetin alfa) with antibody mediated pure red cell aplasia
Dear Health Care Professional:
Amgen Canada Inc., in consultation with Health Canada, would like to bring to your attention changes to the safety information of the Aranesp® (darbepoetin alfa) Product Monograph. Aranesp® is indicated for the treatment of anemia associated with chronic renal failure (CRF), including patients on dialysis and patients not on dialysis; and is indicated for the treatment of anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitantly administered chemotherapy.
The following information is relevant to patients with antibody mediated pure red cell aplasia:
Aranesp® has been approved in Canada since August 2002. As of July 2005, approximately 1,400,000 patients have been treated with Aranesp®, representing 854,000 patient-years of exposure worldwide. Of these patients, a total of two cases of antibody-meditated pure red cell aplasia (PRCA) have been reported and confirmed associated with Aranesp® in patients who have not received other recombinant erythropoietins. This condition has also been observed following treatment with other similar medications (known as erythropoiesis-stimulating proteins). One case of antibody-mediated PRCA was reported in a UK patient with chronic renal failure (CRF). The second case, occurring in a patient with CRF in Canada, has been reported as antibody-mediated PRCA within the context of aplastic anemia.
Since antibody-mediated PRCA has been reported very rarely in patients receiving Aranesp® subcutaneously, the risk/benefit ratio remains favourable and no change in the administration of Aranesp® is recommended.
Any patient with loss of response to Aranesp® should be evaluated for the etiology of loss of effect. A lack of response or failure to maintain a hemoglobin response with Aranesp® doses within the recommended dosing range should prompt a search for causative factors. Deficiencies of folic acid, iron or vitamin B12 should be excluded or corrected. Depending on the clinical setting, intercurrent infections, inflammatory or malignant processes, osteofibrosis cystica, occult blood loss, hemolysis, severe aluminum toxicity, bone marrow fibrosis, insufficient dialysis and malnutrition may compromise an erythropoietic response. PRCA or anti-erythropoietin antibody formation should be excluded. Suspected cases of PRCA in association with Aranesp®, should be reported to Amgen who may assist in this evaluation.
In patients with PRCA secondary to neutralizing antibodies to any erythropoiesis-stimulating proteins, Aranesp® or other erythropoietin products should not be administered as anti-erythropoietin antibodies cross-react with other erythropoietins.
Based on the continuous worldwide safety surveillance of Aranesp® with respect to antibody-mediated PRCA, the Warnings, Precautions, Adverse Reactions, and Information to the Patient sections of the Aranesp® Product Monograph have been updated. No changes in the administration of Aranesp® are recommended. A copy of the revised Product Monograph is available upon request.
It should be noted that reporting rates determined on the basis of spontaneously reported post-market adverse events are generally presumed to underestimate the risks associated with drug treatments.
The identification, characterization, and management of marketed health product-related adverse events are dependent on the active participation of health care professionals in adverse drug reaction reporting programmes. Any occurrences of pure red cell aplasia or other serious and/or unexpected adverse events in patients receiving Aranesp®, should be reported to Amgen Canada Inc. or Health Canada at the following addresses:
Amgen Canada Inc.
6755 Mississauga Road, Suite 400
Mississauga, Ontario
L5N 7Y2
Tel: 1-866-502-6436
Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
Health Canada
Address Locator: 0701C
Ottawa, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca
The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
Should you have any questions or require further information regarding the use of Aranesp®, please contact Amgen Medical Information at 1-866-502-6436.
Sincerely,
original signed by
Jose Iglesias, MD
Medical Director (Oncology)
Medical Affairs, Amgen Canada Inc.